Track topics on Twitter Track topics that are important to you
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the first quarter of 2018 and recent business progress. As quoted in the press release: “We are encouraged by the initial launch of LUXTURNA™ (voretigene neparvovec-rzyl). We are pleased that three … Continued
The post Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress appeared first on Investing News Network.NEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...